IL120303A0 - Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer - Google Patents

Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer

Info

Publication number
IL120303A0
IL120303A0 IL12030397A IL12030397A IL120303A0 IL 120303 A0 IL120303 A0 IL 120303A0 IL 12030397 A IL12030397 A IL 12030397A IL 12030397 A IL12030397 A IL 12030397A IL 120303 A0 IL120303 A0 IL 120303A0
Authority
IL
Israel
Prior art keywords
cancer
alpha1
prevention
treatment
adrenoreceptor antagonists
Prior art date
Application number
IL12030397A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL120303A0 publication Critical patent/IL120303A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL12030397A 1996-03-27 1997-02-24 Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer IL120303A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1422896P 1996-03-27 1996-03-27

Publications (1)

Publication Number Publication Date
IL120303A0 true IL120303A0 (en) 1997-06-10

Family

ID=21764236

Family Applications (2)

Application Number Title Priority Date Filing Date
IL12030397A IL120303A0 (en) 1996-03-27 1997-02-24 Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
IL12049597A IL120495A (en) 1996-03-27 1997-03-20 A drug for the prevention and treatment of cancer that includes 1 α adrenoreceptor antagonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL12049597A IL120495A (en) 1996-03-27 1997-03-20 A drug for the prevention and treatment of cancer that includes 1 α adrenoreceptor antagonists

Country Status (16)

Country Link
US (1) US5935962A (da)
EP (1) EP0799618B1 (da)
JP (1) JPH10101579A (da)
KR (1) KR970064607A (da)
AT (1) ATE294582T1 (da)
AU (1) AU733146B2 (da)
CA (1) CA2201089A1 (da)
DE (1) DE69733169T2 (da)
DK (1) DK0799618T3 (da)
ES (1) ES2242207T3 (da)
HU (1) HUP9700661A3 (da)
IL (2) IL120303A0 (da)
MY (1) MY126321A (da)
NZ (1) NZ314488A (da)
TW (1) TW504386B (da)
ZA (1) ZA972601B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2361627A1 (en) * 1999-01-27 2000-08-10 France Telecom Method, system, device for proving the authenticity of an entity and/or the integrity and/or the authenticity of a message
AU2001285232A1 (en) * 2000-08-24 2002-03-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Alpha-difluoromethylornithine (dfmo) use in the human prostate
DK1293198T3 (da) * 2001-09-14 2005-06-06 Sanol Arznei Schwarz Gmbh Anordning til transdermal indgivelse til behandling af urinkanallidelser
US8222253B2 (en) * 2004-10-23 2012-07-17 Case Western Reserve University Peptide and small molecule agonists of EphA and their uses
US20090062326A1 (en) * 2006-03-17 2009-03-05 Spindel Eliot R M3 muscarinic receptor antagonists for treatment of m3 muscarinic receptor-expressing tumors
WO2009131196A1 (ja) * 2008-04-24 2009-10-29 武田薬品工業株式会社 置換ピロリジン誘導体およびその用途
RU2013125033A (ru) * 2010-06-30 2014-12-10 Галдерма Ресерч Энд Девелопмент Способ предупреждения или лечения кожной опухоли
EP2598129B1 (en) 2010-06-30 2016-05-11 Galderma Research & Development Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor
US20120178757A1 (en) * 2010-12-09 2012-07-12 Nottingham University Hospitals Nhs Trust Method For The Prevention Of Cancer Metastasis
GR20200100456A (el) * 2020-08-03 2022-03-09 Inderes Ltd, Συνδυασμος φαρμακων και χρηση του στη θεραπεια του καρκινου

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4188390A (en) * 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
US4758569A (en) * 1987-08-26 1988-07-19 Pfizer Inc. Doxazosin as an anti-atherosclerosis agent
EP0564093B1 (en) * 1992-04-01 1999-12-01 Pfizer Inc. Hydroxylated metabolites and derivatives of doxazosin as anti-atherosclerosis agents
FR2694495B1 (fr) * 1992-08-05 1994-09-23 Synthelabo Préparation pharmaceutique transdermique contenant de l'alfuzosine.
US5578611A (en) * 1992-11-13 1996-11-26 Synaptic Pharmaceutical Corporation Use of α-1C specific compounds to treat benign prostatic hyperplasia
US5503843A (en) * 1994-04-22 1996-04-02 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents

Also Published As

Publication number Publication date
EP0799618B1 (en) 2005-05-04
JPH10101579A (ja) 1998-04-21
AU733146B2 (en) 2001-05-10
HUP9700661A3 (en) 1999-06-28
ZA972601B (en) 1998-09-28
DK0799618T3 (da) 2005-05-30
HU9700661D0 (en) 1997-05-28
HUP9700661A2 (hu) 1998-11-30
IL120495A0 (en) 1997-07-13
KR970064607A (ko) 1997-10-13
MY126321A (en) 2006-09-29
AU1656997A (en) 1997-10-02
ATE294582T1 (de) 2005-05-15
ES2242207T3 (es) 2005-11-01
EP0799618A2 (en) 1997-10-08
US5935962A (en) 1999-08-10
EP0799618A3 (en) 1997-11-12
CA2201089A1 (en) 1997-09-27
NZ314488A (en) 2000-09-29
IL120495A (en) 2004-09-27
DE69733169T2 (de) 2006-01-19
DE69733169D1 (de) 2005-06-09
TW504386B (en) 2002-10-01

Similar Documents

Publication Publication Date Title
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
UA41355C2 (uk) Засіб для лікування нейро-сніду
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
MY118986A (en) Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
IL120495A0 (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
CA2156481A1 (en) 5-ht2 receptor antagonist compositions useful in treating venous conditions
GR3021813T3 (en) Method of treating alopecia
CA2289017A1 (en) The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer
CZ223199A3 (cs) Použití inhibitorů COMT nebo jejich farmaceuticky vhodných solí nebo esterů pro výrobu léčiva k prevenci diabetických vaskulárních dysfunkcí
IL126158A0 (en) Method for treating substance abuse
WO1995005364A3 (en) Inhibitors of biogenic amine transporters
DE69800906D1 (de) Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie
DK1019066T3 (da) Fremgangsmåder og præparater til forebyggelse og behandling af halsbrand
EP0384302A3 (en) Use of ubenimex in the manufacture of a medicament for treating myelodysplastic syndrome
EE04951B1 (et) R-(+)-alfa-(2,3-dimetoksfenl)-1-[2-(4-fluorofenl)etl]-4-piperidiinmetanooli kasutamine uneh„irete raviks
WO1998025594A3 (en) Lamotrigine in the treatment and prophylaxis of migraine
BR9713828A (pt) Tratamento de tumores altamente vasculares
EA199800820A1 (ru) Способ лечения злоупотребления лекарственными средствами
ZA977873B (en) Dosage form and method for administering drug.
EP1095655A3 (en) NK-1 receptor antagonists and eletriptan for the treatment of migraine
EP1712231A3 (en) Method for improving the pharmacokinetics of tipranavir